EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Diagnosis and Management of Pituitary Adenomas

Nicholas A Tritos, Karen K Miller

JAMA · 25.04.2023 · 329 (16) · 1386

DOI: 10.1001/jama.2023.5444 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 25.04.2023. Verfasst von Nicholas A Tritos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Unit, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Adenoma, Pituitary Neoplasms. Die Arbeit wurde bisher 332-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Pituitary adenomas are neoplasms of the pituitary adenohypophyseal cell lineage and include functioning tumors, characterized by the secretion of pituitary hormones, and nonfunctioning tumors. Clinically evident pituitary adenomas occur in approximately 1 in 1100 persons. Observations Pituitary adenomas are classified as either macroadenomas (≥10 mm) (48% of tumors) or microadenomas (<10 mm). Macroadenomas may cause mass effect, such as visual field defects, headache, and/or hypopituitarism, which occur in about 18% to 78%, 17% to 75%, and 34% to 89% of patients, respectively. Thirty percent of pituitary adenomas are nonfunctioning adenomas, which do not produce hormones. Functioning tumors are those that produce an excess of normally produced hormones and include prolactinomas, somatotropinomas, corticotropinomas, and thyrotropinomas, which produce prolactin, growth hormone, corticotropin, and thyrotropin, respectively. Approximately 53% of pituitary adenomas are prolactinomas, which can cause hypogonadism, infertility, and/or galactorrhea. Twelve percent are somatotropinomas, which cause acromegaly in adults and gigantism in children, and 4% are corticotropinomas, which secrete corticotropin autonomously, resulting in hypercortisolemia and Cushing disease. All patients with pituitary tumors require endocrine evaluation for hormone hypersecretion. Patients with macroadenomas additionally require evaluation for hypopituitarism, and patients with tumors compressing the optic chiasm should be referred to an ophthalmologist for formal visual field testing. For those requiring treatment, first-line therapy is usually transsphenoidal pituitary surgery, except for prolactinomas, for which medical therapy, either bromocriptine or cabergoline, is usually first line. Conclusions and Relevance Clinically manifest pituitary adenomas affect approximately 1 in 1100 people and can be complicated by syndromes of hormone excess as well as visual field defects and hypopituitarism from mass effect in larger tumors. First-line therapy for prolactinomas consists of bromocriptine or cabergoline, and transsphenoidal pituitary surgery is first-line therapy for other pituitary adenomas requiring treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenomaPituitary NeoplasmsAdultChildFemaleHumansPregnancyAdrenocorticotropic HormoneBromocriptineCabergolineHuman Growth HormoneHypopituitarismProlactinoma

Substanzen

Adrenocorticotropic HormoneBromocriptineCabergolineHuman Growth Hormone

Autor:innen und Institutionen

  • Neuroendocrine Unit, Massachusetts General Hospital, Boston.
  • Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Tritos, N. A., & Miller, K. K. (2023). Diagnosis and Management of Pituitary Adenomas. JAMA, 329(16), 1386. https://doi.org/10.1001/jama.2023.5444

Vancouver

Tritos NA, Miller KK. Diagnosis and Management of Pituitary Adenomas. JAMA. 2023;329(16):1386. doi:10.1001/jama.2023.5444

BibTeX
@article{Tritos2023,
  author = {Tritos, Nicholas A and Miller, Karen K},
  title = {Diagnosis and Management of Pituitary Adenomas},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {16},
  pages = {1386},
  doi = {10.1001/jama.2023.5444}
}
Kostenlos starten →